Highlights GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
2.83 ^USD	+0.35%		-3.08%	-63.01%

27/06	GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	MT
27/06	GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	27/06	DJ
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	27/06	CI
Top Midday Decliners	21/05	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	21/05	MT
Top Premarket Gainers	20/05	MT
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting	06/11	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
North American Morning Briefing : Hopes Build for -3-	15/23/15	DJ
GT Biopharma, Inc. Announces Board Changes	04/23/04	CI
North American Morning Briefing : Traders Await -3-	31/23/31	DJ
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/22/01	CI
GT Biopharma Taps Cytovance Biologics as Manufacturing Partner for Leukemia Drug	31/22/31	MT
Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650	31/22/31	CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Highlights

Filters